Abstract
GNE (UDP-N-acetylglucosamine 2-epimerase/ N-acetylmannosamine kinase) is a bifunctional enzyme which catalyzes the conversion of UDP-GlcNAc to ManNAc and ManNAc to ManNAc 6-phosphate, key steps in the sialic acid biosynthesis. Mutations in GNE lead to a neuromuscular disorder, Hereditary Inclusion Body Myopathy (HIBM). A major limitation in understanding the function of GNE is lack of recombinant full length GNE (rGNE) protein for detailed biophysical and structural characterization. In the present study, we have used Dictyostelium discoideum (Dd) as an alternate host for successful expression and secretion of functionally active form of GNE and its mutant proteins. We have generated Dd-AX3 stable cell lines harboring wtGNE or its mutants with Dd specific secretory signal sequence, PsA (prespore antigen). Upon starvation, rGNE was secreted in the medium from secretory vesicles. The rGNE was functionally active with epimerase activity (54±5.2 mU/mg) and kinase activity (66.45±3.48 mU/mg), while both epimerase and kinase activities of mutant GNE were drastically reduced. These activities were found to be statistically significant at p value < 0.05. Our study clearly demonstrates that Dd can be used as an expression host for the production of recombinant and functionally active form of GNE and its mutant proteins that can be used for biophysical characterization and structural determination of GNE to understand the pathomechanism of HIBM.
Keywords: Dictyostelium discoideum, sialic acid, muscle myopathy, secretion, UDP-N-acetylglucosamine 2-epimerase/Nacetylmannosamine kinase, hereditary inclusion body myopathy.
CNS & Neurological Disorders - Drug Targets
Title:Expression and Secretion of Wild Type and Mutant GNE Proteins in Dictyostelium discoideum
Volume: 13 Issue: 7
Author(s): Sonam Grover, Saima Aslam, Vijeta Sharma and Ranjana Arya
Affiliation:
Keywords: Dictyostelium discoideum, sialic acid, muscle myopathy, secretion, UDP-N-acetylglucosamine 2-epimerase/Nacetylmannosamine kinase, hereditary inclusion body myopathy.
Abstract: GNE (UDP-N-acetylglucosamine 2-epimerase/ N-acetylmannosamine kinase) is a bifunctional enzyme which catalyzes the conversion of UDP-GlcNAc to ManNAc and ManNAc to ManNAc 6-phosphate, key steps in the sialic acid biosynthesis. Mutations in GNE lead to a neuromuscular disorder, Hereditary Inclusion Body Myopathy (HIBM). A major limitation in understanding the function of GNE is lack of recombinant full length GNE (rGNE) protein for detailed biophysical and structural characterization. In the present study, we have used Dictyostelium discoideum (Dd) as an alternate host for successful expression and secretion of functionally active form of GNE and its mutant proteins. We have generated Dd-AX3 stable cell lines harboring wtGNE or its mutants with Dd specific secretory signal sequence, PsA (prespore antigen). Upon starvation, rGNE was secreted in the medium from secretory vesicles. The rGNE was functionally active with epimerase activity (54±5.2 mU/mg) and kinase activity (66.45±3.48 mU/mg), while both epimerase and kinase activities of mutant GNE were drastically reduced. These activities were found to be statistically significant at p value < 0.05. Our study clearly demonstrates that Dd can be used as an expression host for the production of recombinant and functionally active form of GNE and its mutant proteins that can be used for biophysical characterization and structural determination of GNE to understand the pathomechanism of HIBM.
Export Options
About this article
Cite this article as:
Grover Sonam, Aslam Saima, Sharma Vijeta and Arya Ranjana, Expression and Secretion of Wild Type and Mutant GNE Proteins in Dictyostelium discoideum, CNS & Neurological Disorders - Drug Targets 2014; 13 (7) . https://dx.doi.org/10.2174/1871527313666140917094905
DOI https://dx.doi.org/10.2174/1871527313666140917094905 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Synergistic Use of Computation, Chemistry and Biology to Discover Novel Peptide-Based Drugs: The Time is Right
Current Pharmaceutical Design Pharmacophore-Based Discovery of New Human Dihydroorotate Dehydrogenase Inhibitor
Medicinal Chemistry Isothermal Calorimetry Study of the Interactions of Type I Antifreeze Proteins with a Lipid Model Membrane
Protein & Peptide Letters Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects
Current Bioinformatics Neurobiological Basis and Pharmacologic Treatment of Social Impairment in Autism Spectrum Disorders
Current Psychopharmacology Age-Related Mitochondrial Alterations without Neuronal Loss in the Hippocampus of a Transgenic Model of Alzheimer's Disease
Current Alzheimer Research Characterisation of Mitochondrial DNA Deletions by Long-PCR in Central Nervous System Regions of Young, Middle- and Old-aged Rats
Current Aging Science L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Curcumin Prevents Neuroinflammation by Inducing Microglia to Transform into the M2-phenotype via CaMKKβ-dependent Activation of the AMP-Activated Protein Kinase Signal Pathway
Current Alzheimer Research Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine The Potential Role of Dysfunctions in Neuron-Microglia Communication in the Pathogenesis of Brain Disorders
Current Neuropharmacology Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging The Genetic Components of Alcohol and Nicotine Co-Addiction: From Genes to Behavior
Current Drug Abuse Reviews Meet Our Editorial Board Member
Current Neuropharmacology Expression, Purification and In Silico Studies of Cold Resistant Protein from Plant Growth Promoting Ps fluorescens Mutant CRPF1
Current Biotechnology Anti-Inflammatory Effects of Physical Activity in Relationship to Improved Cognitive Status in Humans and Mouse Models of Alzheimers Disease
Current Alzheimer Research Synthesis, Molecular Docking and In Vitro Antimicrobial Studies of Novel Pyrazole Analogues of Curcumin
Letters in Drug Design & Discovery Non-Monoamine-Based Approach for the Treatment of Depression and Anxiety Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design